Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-I7 for Mild COVID-19
NCT04501796Phase 1Terminated
- Sponsor
- NeoImmuneTech
- Start
- Nov 2020
- Primary completion
- Jul 2021
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing NT-I7 with Placebo (2 arms). Primary endpoint: Safety of a single dose of NT-I7 at 30 days. Started Nov 2020; status: terminated.
02
Drugs
efineptakin alfa
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04501796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04501796.